Upstate Active Clinical Trials

Study Title:

A031702 - A Phase II Study of Ipilimumab, Cabozatinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

What is the purpose of the study? (in Layman's terms, please describe the study)

Measure disease response in various GU cancers with combination therapy.

Upstate Institutional Review Board (IRB) Number:

1684431

Study/Protocol ID:

A031702

Study Phase:

Phase 2

Patient Age Group:

Adults

Principal Investigator:

Alina Basnet

Who is eligible?

Patients with metastatic gentrourinary cancer who have received up to 2 prior therapies.

What is involved if I participate?

• How long is the study?
  5 years
• Is transportation provided or reimbursed?
  No
• Is parking provided or reimbursed?
  No
• What tests and procedures are involved?
  blood work, CT scans, questionnaires,

Where will the study take place?

SUNY Upstate Medical University Downtown Campus

Other Information:

A031702

Who can I contact for more information?

Name: Jennifer Newman
Phone: 315-464-8230
Email: [email protected]

Return to Previous Page || Search Again